ProShares Trust - ProShares MSCI EAFE Dividend Growers ETF
EFAD
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $29.76 Billion |
|---|---|
| Enterprise Value | $29.59 Billion |
| Dividend Yield | $1.20 (2.80%) |
| Earnings per Share | $- |
| Beta | 0.84 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2265.7 |
| Enterprise Value to EBIT | -393.61 |
| Enterprise Value to Net Income | -420 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.20%▲ 1.86% |
|---|---|
| Total Invested | $34.47M▼ 2.94% |
| Investors Holding | 28▲ 1.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
This committee controls taxation (corporate profitability) and entitlement spending (Medicare/Medicaid reimbursement rates), which are critical determinants of a future drug manufacturer's market access and revenue.
This committee allocates federal spending, including critical funds for the NIH (research funding) and FDA (regulatory capacity), directly impacting the operational environment and potential funding for biotech firms.
This committee directly oversees the FDA (drug approval process) and NIH (biomedical research funding), which are fundamental to a biopharmaceutical company's operations, R&D, and market access.
This committee's oversight of intellectual property (patents) is critical for a biopharmaceutical company, directly impacting its ability to protect its drug discoveries and future revenue streams.